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Although the cost of coping with Alzheimer’s disease (AD) is already substantial—measured in lost
quality of life and decreased productivity as well as in dollars—near-term predictions indicate that
the expensewill soon be toomuch for society to bear. The current lack of effective therapies, a large
aging population, and increasing life expectancy worldwide are rapidly converging into an impend-
ing crisis for health care providers. Significant efforts are underway to reverse this dismal trend, and
several recent articles reveal promising advances on all fronts in the fight to understand and treat
AD. In this Select, we highlight recent research that brings much-needed insight to the under-
standing of disease mechanisms and the development of effective treatments for AD.Medial surface projects of the brain demon-
strate the absence of amyloid plaque in non-
carriers of the gene (top left). In the pre-symp-
tomatic phase of Alzheimer’s in this cohort,
amyloidplaquesarewidespread,mostnotably
in the medial parietal lobe (bright green area).
Amyloid plaque burden continues to increase
in participants with mild symptoms and in
those with dementia. Amyloid plaque burden
was measured using [11C]PiB PET imaging;
imagesshowquantitativestandardized uptake
value ratios (SUVRs). Image courtesy T. Ben-
zinger and T. Blazey, DIAN Imaging Core.Observing AD before the Decline
AD develops slowly, and it is believed that pathological events begin decades
beforemeasurable symptoms appear, complicating studies into bothmechanism
and treatment. A recent paper from Bateman et al. (2012) presents results from
a prospective cross-sectional analysis of the Dominantly Inherited Alzheimer
Network (DIAN) longitudinal study. In this study, unaffected individuals and indi-
viduals from families afflicted with autosomal dominant AD were evaluated to
characterize several biochemical markers for AD, as well as brain physiology
and metabolism. The results confirm that biochemical and physiological
changes, and thus the underlying biological processes, can be detected years
before symptoms present and help piece together a timeline of pathological
events. The authors compared cognitive function, brain physiology, and levels
of relevant biomarkers—such as levels of the plaque forming proteins amyloid
b (Ab) or Tau in cerebrospinal fluid or blood—between noncarriers and carriers
of AD-related mutations in PSEN1, PSEN2, and APP. When participants were
sorted according to time from expected onset of symptoms (defined as the differ-
ence between the age of the participant and the parental age of first symptom
onset), the results demonstrate that differences are apparent asmany as 20 years
prior to expected symptom onset. A similar demonstration in cases of sporadic
AD is needed before wide-spread application of these results for diagnostic pur-
poses can be made. Nevertheless, the data raise interesting points about the
sequence of biological events that precede cognitive decline and indicate that
clearance of pathogenic Ab may be the most useful early-intervention strategy.
Bateman, R.J., et al. (2012). N. Engl. J. Med. 367, 795–804.Under conditions where expression
levels of LDLR are increased (as shown
here on a neuron and an astrocyte) and
binding ApoE, Ab is not retained in the
brain interstitial fluid and more of the
peptide is cleared from the brain to
the blood. Image courtesy of Joseph
Castellano.Taking Out the Trash
Removing pathogenic Ab to prevent, and possibly reverse, aggregation is the most
sought aftermethod for slowingor delaying theonset of AD. In a recent study, Castellano
et al. (2012) clarify andelaborate ononemechanism for promotingAb clearance from the
brain to theblood,where thehalf-life of thepeptide is only a fewminutes. Several variants
of the ApoE gene, which encodes the Ab-interacting protein apolipoprotein E, are the
strongest genetic predictors for the risk of developing sporadic, late-onset AD. In this
report, increased expression of the ApoE-interacting low-density lipoprotein receptor
(LDLR) in a transgenic model of human APP expression increased Ab clearance from
the brain, as measured by a novel antibody-stabilizing protocol that allowed direct
measurementof endogenousAb transported into theblood fromthebrain. This suggests
that modulating LDLR levels, or the LDLR-ApoE interaction, could be one way of
improving Ab clearance years before symptoms are obvious. Although other LDL recep-
tors directly interact with Ab and are involved in its clearance, the authors note that the
relatively limitednumberof substrates for LDLRmaymake it easier tocreate therapeutics
with a greater specificity for the ApoE/Ab system, warranting further research into this
particular pathway for reducing Ab levels in the brain.
Castellano, J.M. (2012). Proc. Natl. Acad. Sci. USA. Published online August 27, 2012. http://dx.doi.org/10.1073/pnas.
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Confocal microscopy of mitochondria-
localized GFP reveals elongated mito-
chondria in neuronal cell bodies of
human tau-expressing flies. Photo cour-
tesy of Brian DuBoff.Mitochondrial Dysfunction in Neurodegeneration:
Tau and DRP1
Two recent papers provide new insights into the roles that mitochondria and mito-
chondrial abnormalities play in neurodegeneration and AD, and the first we discuss
is an article by DuBoff et al. (2012) on the effects of tau on mitochondrial fission. Dys-
regulation of mitochondrial size, by disrupting either fusion or fission, prevents proper
mitochondrial function and leads to cytotoxicity and cell death. Both tau accumulation
and disrupted mitochondrial dynamics have been frequently implicated in neurode-
generative diseases, including AD, and both mechanisms can contribute to neuronal
death. Nevertheless, many details, including the sequence of molecular events
leading to cell death, have remained unknown. DuBoff et al. (2012) present for the first
time a strong molecular link between the two processes. Using both Drosophila and
mousemodels, their experiments describe both the physical interactions and order of
events that lead to cell death. The authors show that transgenic tau accumulation
disrupts the colocalization of mitochondria with fission protein DRP1 by stabilizing
F-actin. The dynamic regulation of actin is crucial for the physical association of mito-
chondria and DRP1 that is required for fission, and stabilization of F-actin by tau
prevents this association. The failure of actin to properly organize DRP1 and mito-
chondria leads to elongated mitochondria, eventual organelle dysfunction, and rapidcell death. Preliminary experiments expressing a pseudohyperphosphorylated mutant of tau, tauE14, showed even greater
mitochondrial elongation, suggesting that organelle disruption is also downstream of phosphorylation.
DuBoff, B., et al. (2012). Neuron, 75, 618–632.Lipid droplets (bright green dots) are deposited in
fibroblasts from Alzheimer disease patients, but
not in normal cells. These droplets reflect one of
themany aspects of derangedMAM function found
in AD. Photo courtesy of Estela Area-Gomez,
Columbia University.Mitochondria, ER, and MAMs
Mitochondrial-associated endoplasmic reticulum membranes, or MAMs,
are critical points of physical interaction between the endoplasmic reticulum
(ER) and mitochondria, serving as integral hubs in Ca2+ signaling, lipid traf-
ficking, and cellular homeostasis. As compared with other regions of the
ERmembrane, MAMs are also enriched for several molecules whose activity
is the foundation for AD: the precursor protein for the toxic Ab peptide, APP,
as well as the presenilins (PS-1 and PS-2), which are integral membrane
components of the g-secretase complex that processes APP into Ab
peptides. Mutations in the presenilins, or in APP, are found in a majority of
cases of familial AD and lead to the increased production of Ab42, the toxic
isomer of Ab. In a second article touching upon mitochondrial dysfunction in
neurodegeneration, Area-Gomez et al. (2012) pursue the intriguing hypoth-
esis that increased activity of MAMs, and disrupted ER-mitochondrial com-
munication, may be the unifying link for many disparate aspects of cellular
dysfunction in AD. Using a variety of cell lines and tissues related to AD,
they elaborate on previous results to describe howmutant presenilins accu-
mulate in MAMs, and they show that mutations in the presenilins correlate
with increased MAM function and increased association between ER and
mitochondria. Increased MAM activity is observed in cells from patients
with either familial or sporadic AD, even in those cases where mutations
are not observed in the presenilins, supporting the hypothesis that MAM
activity is central to several pathways important for the development of
AD. Their results may help create a holistic vision of the cellular dysfunction
that leads to neurodegeneration in AD.
Area-Gomez, E., et al. (2012). EMBO J. Published online August 14, 2012.http://dx.doi.org/10.1038/emboj.2012.202.
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